2023-11-01 15:05:07 ET
A Paris-based %Healthcare company saw an insanely bullish session on Wednesday after it was announced that %AstraZeneca (Nasdaq: ) said it will acquire a stake in the company and enter into research collaboration, according to a press release.
Shares of %Cellectis (Nasdaq: ) went soaring on the news, with shares of this small cap reaching $2.99/share (+208.25%) at the session high. This move erased the majority of the losses this stock saw this summer.
Cellectis SA is a %Biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.